(BUSINESS WIRE)–Jan. 29, 2015– ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that it will report its fourth quarter and year-end 2014 financial results and issue 2015 financial guidance on Thursday, February 19, 2015, before the market opens. Following the announcement, at 8:30 a.m. Eastern Time, company management will host a conference call and webcast discussion of the results and provide a general corporate update. The live webcast can be accessed by visiting the investor relations section of the Company’s website at http://investor.ariad.com. The call can be accessed by dialing… Read more »

Shares of Ariad Pharmaceuticals closed yesterday at $6.55 . ARIA has a 1-year high of $9.22 and a 1-year low of $4.90. The stock’s 50-day moving average is $6.60 and it’s 200-day moving average is $6.10.

On the ratings front, Ariad Pharmaceuticals has been the subject of a number of recent research reports. In a report issued on January 13, J.P. Morgan analyst Cory Kasimov maintained a Hold rating on ARIA. Separately, on the same day, Cowen’s Phil Nadeau maintained a Hold rating on the stock and has a price target of $4.50.

In total, one research analyst has rated the stock with a Sell rating, 2 research analysts have assigned a Hold rating and one research analyst has given a a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $6.55 which is -5.8% under where the stock closed yesterday.

Ariad Pharmaceuticals Inc is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules.